Hepatic Arterial Therapy with Drug-Eluting Beads in the Management of Metastatic Pancreatic Carcinoma to the Liver: A Multi-Institutional Registry

Table 3

Bead catheter infusion outcomes.

	𝑁 = total treatments = 17
Number of bead courses	Median −1.5; (range) (1–3)
Technical success	100%
Dosage delivered (median, range)	(100, 25–150)
Total hepatic dose exposure for all LC; Irinotecan; Doxorubicin	Beads; 250 mg (100–400); 150 mg (100–450)
Bead size utilized
100–300 μ; 300–500 μ; 500–700 μ	13; 4; 0
Complications	4 (24%)
Extrahepatic infusion	0
Hematologic changes
WBC; HGB; Bilirubin	−0.23 (−.45–3.0); 0.8 (−1.1–2.1); 0.3 (−0.4–0.8)